Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

F

Fondazione Italiana Linfomi - ETS

Status

Completed

Conditions

Follicular Lymphoma

Treatments

Other: Metabolic activity measured by FDG-PET

Study type

Observational

Funder types

Other

Identifiers

NCT03525665
FIL_PETRA

Details and patient eligibility

About

The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.

Full description

The study does not require any intervention on the patient, but it involves the simple collection of data that are already present in the medical record. Since this is a retrospective study, it will not require further analysis or diagnostic investigations than those already made.

Enrollment

175 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with initial diagnosis of follicular lymphoma since 2001
  • Histological confirmation of follicular lymphoma, grade I, II, III according to WHO 2008 classification, at the time of initial diagnosis
  • Systemic first-line treatment with immuno-chemotherapy
  • PET availability at the time of response after first-line treatment (optional)
  • Clinical and radiological evidence of FL relapse or progression
  • Histological confirmation of relapse (strongly recommended)
  • PET availability of at the time of relapse/progression and images available for central assessment
  • Availability of clinical, laboratory and therapeutic treatment data at the time of initial diagnosis and relapse/progression
  • Follow up of at least 12 months after relapse/progression

Exclusion criteria

  • None

Trial contacts and locations

27

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems